Eliminate Thromboembolism: Improving Anticoagulation in Non-valvular Atrial Fibrillation Patients

CompletedOBSERVATIONAL
Enrollment

251

Participants

Timeline

Start Date

February 29, 2016

Primary Completion Date

May 31, 2018

Study Completion Date

May 31, 2018

Conditions
Atrial Fibrillation
Trial Locations (21)

18901

Doylestown Health Cardiology, Doylestown

23601

Riverside Cardiology Specialists, Newport News

28358

Duke Cardiology of Lumberton, Lumberton

29203

Columbia Heart Clinic, PA, Columbia

30041

Atlanta Heart Specialists, Cumming

30350

Atlanta Institute for Medical Research, Inc., Atlanta

33065

Holy Cross Medical Group, Coral Springs

33952

Charlotte Heart Group, Port Charlotte

39216

Jackson Heart Clinic, Jackson

42303

Research Integrity, LLC., Owensboro

46321

Cardiovascular Research of Northwest Indiana, L.L.C., Munster

49085

Great Lakes Heart and Vascular Institute, Saint Joseph

49707

Endeavor Medical Research, Alpena

55102

HealthEast Medical Research Institute, Saint Paul

70121

Ochsner Health System, New Orleans

75013

North Texas Research Associates, Allen

76712

Providence Health Center, Waco

91105

Foothill Cardiology, Pasadena

04856

Penobscot Bay Medical Center, Rockport

08318

Cardiovascular Associates of the Delaware Valley, Elmer

08043

Lourdes Cardiology Services, Voorhees Township

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

collaborator

Pfizer

INDUSTRY

lead

Duke University

OTHER